# Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

> **NCT04966338** · PHASE3 · COMPLETED · sponsor: **Cinnagen** · enrollment: 170 (actual)

## Conditions studied

- Multiple Sclerosis
- Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** Ocrelizumab (CinnaGen, Iran)
- **BIOLOGICAL:** Ocrelizumab (Roche, Switzerland)

## Key facts

- **NCT ID:** NCT04966338
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-19
- **Primary completion:** 2020-11-09
- **Final completion:** 2021-10-01
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04966338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04966338, "Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04966338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*